|
시장보고서
상품코드
2076239
제VIII 인자 결핍증 치료 시장 : 제품 유형별, 유통 채널별, 지역별Global factor VIII deficiency treatment Market, By Product Type, By Distribution Channel, And by Region |
||||||
세계의 제VIII 인자 결핍증 치료 시장은 2026년에 29억 3,110만 달러 규모에 달할 것으로 추정되고 있으며, 2033년에 42억 760만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.3%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 29억 3,110만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 5.30% | 2033년 시장 규모 예측 : | 42억 760만 달러 |
혈우병은 일반적으로 혈액이 제대로 응고되지 않는 유전성 출혈성 질환입니다. 이로 인해 자발적인 출혈이나 외상·수술 후 출혈이 발생할 수 있습니다. 혈액에는 출혈을 멈추는 데 도움이 되는 다양한 응고 단백질이 포함되어 있습니다. 혈우병 환자는 제VIII인자(8) 또는 제IX인자(9) 중 하나의 농도가 낮습니다. 혈액내 응고 인자의 양에 따라 혈우병의 중증도가 결정됩니다. 응고 인자의 양이 줄어들수록 심각한 건강 문제를 일으킬 수 있는 출혈 위험이 높아집니다. 혈우병은 혈액 응고에 필요한 응고 인자 단백질을 합성하기 위한 지시를 내리는 유전자 중 하나에 돌연변이 또는 변화가 발생함으로써 유발됩니다. 이러한 변화나 변이로 인해 응고 단백질이 정상적으로 기능하지 못하거나 완전히 결핍될 수 있습니다.
시장 역학
합리적인 가격의 혈우병 치료 옵션에 대한 접근성을 개선하기 위해 정부와 비정부 기구의 노력이 늘어나고 있습니다. 혈우병의 발병률과 유병률 상승은 예측 기간 중 시장 성장을 촉진할 것으로 예상되며, 이에 따라 주요 기업이 시장의 미충족 수요를 충족시키기 위해 신제품을 출시하게 될 것입니다. 제품 출시 및 치료와 관련된 유리한 규제 환경과 지침 역시 예측 기간 중 시장 성장을 지원할 것으로 예상되는 주요 요인입니다. 새로운 혈우병 치료법 개발에 나선 주요 시장 진입 기업의 연구개발 활동이 활발해짐에 따라 예측 기간 중 시장 성장을 더욱 견인할 것으로 전망됩니다. 예를 들어 2023년 4월 4일, 다국적 제약·헬스케어 기업인 사노피(Sanofi S.A.)는 성인 A형 혈우병 치료에 사용되는 후보 약물 ‘피투시란(fitusiran)'를 활용한 3상 임상시험의 긍정적인 결과를 발표했습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 유형의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수(기업 개요, 제품 유형 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 제8인자 결핍증 치료 시장의 주요 기업 개요을 발표하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 유형 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 제8인자 결핍증 치료 시장' 보고서는 투자자, 공급업체, 제품 유형별 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 제8인자 결핍증 치료 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 제VIII 인자 결핍증 치료 시장 : 제품 유형별, 2021-2033년
제5장 세계의 제VIII 인자 결핍증 치료 시장 : 유통 채널별, 2021-2033년
제6장 세계의 제VIII 인자 결핍증 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.09Global factor VIII deficiency treatment Market is estimated to be valued at USD 2,931.1 Mn in 2026 and is expected to reach USD 4,207.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,931.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 4,207.6 Mn |
Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This may result in both spontaneous bleeding and bleeding after injuries or surgery. Blood contains a variety of clotting proteins that can aid in stopping bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The quantity of factors in a person's blood determines the severity of their hemophilia. The likelihood of bleeding, which can cause serious health issues, increases as the amount of the factor decreases. Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. This change or mutation can prevent the clotting protein from working properly or be missing altogether
Market Dynamics
Increase in the government and non-government organizations initiatives to improve access to affordable hemophilia treatment options. Rising incidences and prevalence of hemophilic disorder are expected to boost the growth of the market over the forecast period which leads to product launches in the market by the key players, to fulfill the unmet need of the market. Favorable regulatory scenarios and guidelines for product launches and treatment are other leading factors that are expected to propel the growth of the market over the forecast period. An increase in the research and development activities by key market players to develop novel hemophilia treatment options is further expected to drive market growth for the forecast period. For instance, on April 4, 2023, Sanofi S.A., a multinational pharmaceutical and healthcare company, announced the positive result of their phase-III clinical trials using fitusiran, a drug candidate used to treat hemophilia-A in adults.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new Product Type launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global factor VIII deficiency treatment market based on the following parameters - company highlights, Product Types portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Baxter, Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product type launches, type up-gradation, market expansion, and marketing tactics
- The Global factor VIII deficiency treatment market report caters to various stakeholders in this industry including investors, suppliers, product type manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global factor VIII deficiency treatment market
Detailed Segmentation:
- Global Factor VIII Deficiency Treatment Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Biologic (Hemlibra)
- Desmopressin
- Global Factor VIII Deficiency Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Factor VIII Deficiency Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Company Profiles
- Baxter*
- Company Highlights
- Product Types Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biogen, Inc.
- Bayer AG
- CSL Behring
- Ferring B.V.
- F. Hoffmann-La Roche AG
- Pfizer, Inc.
- Kedrion
- Novo Nordisk A/S
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Recent Product Type Launches/Approvals
- Epidemiology
- Merger, Acquisition, Collaborations Scenario
- Regulatory Scenario
- PEST Analysis
- Porter's Five Forces Analysis
- Pricing Analysis
- Brand Analysis
4. Global Factor VIII Deficiency Treatment Market, By Product Type, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Plasma Derived Coagulation Factor Concentrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Recombinant Coagulation Factor Concentrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Biologic (Hemlibra)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Desmopressin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Factor VIII Deficiency Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Factor VIII Deficiency Treatment Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- Japan
- India
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Baxter
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen, Inc.
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CSL Behring
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ferring B.V.
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kedrion
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
